A Phase 2 interventional study of ETC-1002 and Atorvastatin in Hyperlipidemia, sponsored by Esperion Therapeutics, Inc.. Completed at 19 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-03-29.
Sponsored by Esperion Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 338 studies in Hyperlipidemias with a site in United States — 30 open to participants now, 45 under way, 10 of them phase 3. Hyperlipidemias · United States.
Among the 338 studies in Hyperlipidemias with a site in United States, this one is the 189th largest by enrollment of the 306 interventional ones that give a count, is one of 18 that started in 2015, is one of 43 in phase 2, and was the 212th registered.
862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.
Browse Hyperlipidemias studies →30 of the 338 studies in Hyperlipidemias with a site in United States are open now. Recruiting first, the newest first:
Arrowhead Pharmaceuticals · Sites in United States, Denmark, Poland
Ages 12–17
University of Alabama at Birmingham · Sites in United States
Ages 18+ · Men only
Colorado Prevention Center · Sites in United States
Ages 18+
University of Alabama at Birmingham · Sites in United States
Ages 30–79 · Women only
Cambridge Health Alliance · Sites in United States
Ages 18–60
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
338 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 34 · Phase 2 54 · Phase 3 77 · Phase 4 23
First in 1976; this study’s year is marked. 18 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 68 is below the median of 88 across 735 interventional studies indexed under Hyperlipidemias.
Median enrollment 120 across the 306 interventional studies, 104 across the 29 observational. Of the 271 that completed or were terminated, 109 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
119 of 338 have an industry lead sponsor. The 10 most frequent:
Esperion Therapeutics, Inc. is the lead sponsor of 24 studies on the registry; 1 is open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
Esperion Therapeutics, Inc. has 9 studies filed under Hyperlipidemias — fewer than ten, so there is no comparison to draw.
20 of the studies in Hyperlipidemias with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04951219Phase 3Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) | 2027-03 |
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT02262832Phase 3National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy | 2027-07-31 |
| NCT06305559Phase 3NewAmsterdam PharmaA CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque | 2027-11 |
| NCT06062394University of PennsylvaniaPenn Medicine Healthy Heart | 2026-12 |
Add all 20 to your calendar (.ics) → With an account.
Among the 338 studies in Hyperlipidemias with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this research study is to measure the amount of atorvastatin and ETC-1002 in the blood, to determine how ETC-1002 affects the level of LDL-cholesterol (bad cholesterol) and other markers of health and disease in blood and urine, and to see how ETC-1002 is tolerated in the body compared to placebo when added to stable atorvastatin 80 mg background therapy in statin-treated patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ETC-1002 180 mg treatment, oral once daily added-on to Atorvastatin 80 mg once daily
Drug: ETC-1002 · Drug: Atorvastatin
Placebo treatment, oral once daily added-on to Atorvastatin 80 mg once daily
Drug: Atorvastatin · Drug: Placebo
Blinded ETC-1002 180 mg tablet once daily for 4 weeks (Weeks 1 to 4)
Also known as: bempedoic acid
Atorvastatin 80 mg tablet once daily for 8 weeks (Weeks -4 to 4)
Blinded ETC-1002-matched placebo tablet once daily for 4 weeks (Weeks 1 to 4)
Peak plasma concentration (Cmax) pharmacokinetics of atorvastatin and its active metabolites
Fold change in Cmax from prior-to to following 2 week treatment with ETC-1002
Time frame: 2 weeks
24-hour area under the curve (AUC) pharmacokinetics of atorvastatin and its active metabolites
Fold change in AUC from prior-to to following 2 week treatment with ETC-1002
Time frame: 2 weeks
Percent change in LDL-cholesterol
Percent Change from baseline to 4 week treatment, incremental lowering of LDL-C
Time frame: 4 weeks
Percent change in hsCRP
Percent change from baseline to following 4 week treatment with ETC-1002
Time frame: 4 weeks
Percent change in total cholesterol
Percent change from baseline to following 4 week treatment with ETC-1002
Time frame: 4 weeks
Percent change in non-HDL-cholesterol
Percent change from baseline to following 4 week treatment with ETC-1002
Time frame: 4 weeks
Percent change in apolipoprotein B
Percent change from baseline to following 4 week treatment with ETC-1002
Time frame: 4 weeks
24-hour post dose plasma concentration pharmacokinetics of ETC-1002 and its active metabolite
Fold change in trough exposure from prior-to to following 2 week treatment with ETC-1002
Time frame: 2 weeks
Plan to share: Undecided
The record gives a start of Dec 2015, a primary completion of Jul 2016 and a completion of Jul 2016. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bempedoic acid